Market revenue in 2023 | USD 16.6 million |
Market revenue in 2030 | USD 30.3 million |
Growth rate | 9% (CAGR from 2023 to 2030) |
Largest segment | Kallikrein inhibitor |
Fastest growing segment | Kallikrein inhibitor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 45.18% in 2023. Horizon Databook has segmented the Argentina hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
Argentina lacks proper healthcare coverage, and over 36% of its population does not have any formal healthcare coverage & is dependent on the public healthcare system. However, its healthcare expenditure is also 1.1% higher than the average of the Latin American region.
Increasing government initiatives, coupled with the rising incidence of HAE, are expected to drive the market over the forecast period. The country shows the highest prevalence of the condition, with around one in every 10,000 being diagnosed with the condition.
Moreover, key players operating in the market are focusing on product launch & approval to bring products into the market and help curb the condition. For instance, in November 2023, BioCryst Pharmaceuticals, Inc. received ANMAT approval for ORLADEYO (berotralstat) in Argentina for the prophylaxis of HAE attacks in pediatric and adult patients.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Argentina hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account